Bioinnovo SA was part of a multidisciplinary team responsible for the development of avian IgY antibodies that neutralize the virus causing COVID-19 The project, “Development and production of critical reagents for COVID-19 diagnosis and treatment: […] See more

Algenex, the Spanish company delivering recombinant technologies, a key factor for the development of Vedevax BLOCK, has opened a new production plant for vaccines in the suburbs of Madrid*. The new facility has the capacity […] See more

Specialists of the National Institute of Industrial Technology (INTI) and the national company Ivema Desarrollos designed an essential device for a rapid diagnostic test to substitute imports, reduce costs to the half and meet the […] See more

The Andean Country authorized the commercialization of Vedevax Block, the first recombinant vaccine for the control of the virus. The product developed by Bioinnovo SA, a company created by a partnership between the National Institute […] See more

The constant Research and Development is a principle of Vetanco DNA and the reason why a major part of its budget is allocated to that purpose. For Vetanco, being on the cutting-edge is rewarding because […] See more

Due to the rising interest in Biotech Vac. Technology, Sherry Layton, Chief Scientific Officer of Vetanco USA, was invited to develop the subject: “Reducing The Use Of Antimicrobials Through Innovative Universal Subunit Vaccine Platform Design.” […] See more

What follows is a general outlook of the reality that pig farming in the United States has been facing, especially in the slaughter area. In the video, our colleague, Jeffrey W. Hall, Director of Research […] See more

Bioinnovo, the public-private company (INTA–Vetanco) made its first contribution to the macro collaborative project conducted by a scientific committee that brings together more than twenty male and female researchers from different institutions. Those institutions are […] See more